Full-Time

Material Coordinator

Supply Chain Operations

Posted on 6/12/2025

Deadline 9/30/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$47k - $60k/yr

+ Incentive Cash + Stock Opportunities

Mid

Company Historically Provides H1B Sponsorship

Middlesex, NJ, USA

In Person

Category
Inventory Management
Supply Chain Management
Operations & Logistics
Required Skills
Oracle
Requirements
  • Ability to work as team
  • Intermediate written and verbal communication and mathematical skills
  • Introductory Proficiency in MS Office applications
  • Inventory control and management including lot / batch segregation, expiration dating, and temperature storage requirements
  • Advanced warehouse management system experience
Responsibilities
  • Records patient material handling / operations data and information in a clear, concise, format according to proper cGxP requirements
  • Performs inspection and receipt of incoming patient materials per cold chain shipping requirements in coordination with defined specifications and in collaboration with Incoming Quality Control
  • Performs inventory control: cycle counts, material stocking, scrapping, destruction
  • Completes inventory / material transfer and movement within facility
  • Manages material expiry, lot / batch control, allocation and maintains material condition requirements
  • Maintains timing according to the production schedule to ensure on-time material transfers and availability
  • Completes transactions within an electronic data management system, i.e. Oracle
  • Performs inspection and receipt of incoming Apheresis and PBMC and prepares final product shipments for couriers
  • Quantifies and maintains materials in production dispensary
  • Perform apheresis receipt of incoming raw materials and prepares final product shipments for couriers
  • Maintains timing according to the production schedule to ensure on-time logistics
  • Records material handling data and information in a clear, concise, format according to proper GDPs
  • Works in a team based, cross-functional environment to complete warehousing tasks required by shift schedule
  • Must be able to work in an environment with blood derived components
  • Completes training requirements in accordance to defined schedule / curricula
  • Periodically reviews and provides input on revisions to SOPs related to functional responsibilities
  • Provides support for investigations and issue resolution
  • Assists with resolution of inbound issues (receiving, suspect damages, shipment errors)
  • Identifies process and performance improvement opportunities
  • Collaborates cross functionally with Manufacturing, Quality, Materials Management, Process & Technology
Desired Qualifications
  • Background to include an understanding of biology, chemistry, medical or clinical practices preferred, not required
  • ERP experience preferred, not required

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • Advancements in targeted protein degradation enhance therapeutic offerings in oncology.
  • Partnership with BioNTech could provide a competitive edge against Merck's Keytruda.

What critics are saying

  • Antitrust litigation over Pomalyst could impact BMS's market position in oncology.
  • Reliance on real-world data presents challenges in data quality and implementation.
  • High costs and technical challenges in space research could affect treatment feasibility.

What makes Bristol Myers Squibb unique

  • BMS collaborates with BioNTech for next-gen cancer immunotherapy, enhancing oncology portfolio.
  • Focus on real-world data strategies could lead to faster drug market entry.
  • Developing bone disease treatments in space positions BMS as a leader in innovative research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ISS National Lab
Jul 7th, 2025
This is Not the Time to Cut Space-enabled Medical Research

Bristol-Myers Squibb is developing novel bone disease treatments in space, and the National Stem Cell Foundation is studying 3D brain organoids derived from patients with Parkinson's disease in microgravity to observe disease progression more rapidly with the aim of identifying potential biomarkers for early diagnosis and therapeutic targets.

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

Unlearn
Jun 24th, 2025
The Best 15 Minutes You'll Spend on Clinical Trials Today

At the 2025 "Digital Breakthrough for Pharma" Summit hosted by Bristol Myers Squibb, Unlearn's co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

INACTIVE